2001, Number 3
<< Back Next >>
Arch Cardiol Mex 2001; 71 (3)
Participation of the tumor necrosis factor alpha in atherosclerosis
Rodríguez-Maldonado E, Hernández-Rebollar AE, López-Marure R, Massó F, Montaño LF
Language: Spanish
References: 91
Page: 241-249
PDF size: 203.94 Kb.
ABSTRACT
We describe tumour necrosis factor alpha and its role in the development of the atherosclerotic lesion, and detail the effects of this cytokine upon vascular endothelial cells under normal and high risk conditions. We propose that TNF-α performs a central role in the progression of the lesion since, once the endothelial cell feedback regulatory mechanisms are altered, there is an increase in the microenvironment TNF-α concentration, which together with some of the already well known risk factors, generates an environment that favours and perpetuates the development of the atheromatous lesion.
REFERENCES
Posadas-Romero C, Tapia-Conyer R, Lerman-Garber I, Zamora-González J, Cardoso-Saldana G, Salvatierra-Izaba B et al: Cholesterol levels and prevalence of hypercholesterolemia in a Mexican adult population. Atherosclerosis 1995; 118: 275-284.
Rodríguez Saldaña J, Cantú Brito C, Sosa Espinosa O, Reynoso Marenco MT, Zuckermann Foullon D, Barinagarrementeria Aldatz F: Prevalence of carotid atherosclerosis in a cohort of Mexico City. Arch Inst Cardiol Mex 1998; 68: 44-50.
Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
Vogel RA: Coronary risk factors, endothelial function. and atherosclerosis: a review. Clin Cardiol 1997; 20: 426-432.
Metha JL, Saldeen TGP, Rand KR: Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol, 1998; 31: 1217-1225.
Munro JM, Cotran RS: The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab invest 1988; 58: 249-261.
Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA: Atherosclerosis: basic mechanisms. Oxidation. inflammation and genetics. Circulation 1995; 91: 2488-2496.
Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115.126.
Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS: Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human diseases. J Interferon Cytokine Res 1999; 19: 91-104.
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induce serum factor that causes necrosis of tumours. Proc Nad Acad Sci USA 1975; 72: 3666-3670.
Mantovani A, Bussolino F, Introna M: Cytokine regulation of endothelial cell function: from molecular level to bedside. Immunol Today 1997; 18: 231-240.
Aggarwal BB, Khor WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, et al: Human tumour necrosis factor. Production purification and characterization. J Biol Chem 1985; 260: 2345-2354.
Wang AM, Creasey AA, Landner MB, Lin LS, Van Arsdell JSJN, Yamamoto R, et al: Molecular cloning of the complementary DNA for human tumour necrosis factor. Science 1985; 288: 149-154.
Shirai T, Yamaguchi H, Ito H, Todd CW, Wallace B: Cloning and expression in Escherichia coli of the gene, for human tumour necrosis factor. Nature 1985; 313: 803-806.
Jones EY, Stuart DI, Walker NPC: Structure of tumour necrosis factor. Nature 1989; 338: 225-228.
Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, et al: Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312: 724-729.
Kriegler M, Perez C, DeFay K, Albert I, Lu SD: A novel form of TNF/cachectin is a cell surphace cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53: 45-53.
Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, Ware C: A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 1995; 181: 1205-1210.
Moss ML, Jin SL, Milla ME, Brkhart W, Carter HL, Chen WJ, et al: Cloning of a desintegrin metalloprotease that process precursor tumour-necrosis factor. Nature 1997; 385: 729-733.
Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A: Purification of cachectin a lipoproteinlipase-supressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 1985; 161: 984-995.
Nissen-Meyer J, Hammerstrom J: Physicochemical characterization of cytostatic factors released from human monocytes. Infect Immun 1982; 38: 67-73.
Dubravec DB, Spriggs DR, Mannick JA, Rodrick ML: Circulating human peripheral blood granulocytes synthesise and secrete tumour necrosis factor alpha. Proc Natl Acad Sci USA 1990; 87: 6758-6761.
Warner SJC, Libby P: Human vascular smooth muscle cells: target for and source of tumour necrosis factor. J Immunol 1989; 142: 100-109.
Trinchieri G: Regulation of tumour necrosis factor production by monocytes, macrophages and lymphocytes. Immunol Res 1991; 10: 89-103.
Kahaleh MB, Zhou S: Induction of tumour necrosis factor (TNF) synthesis by endothelial cells upon exposure to rTNF. Arthritis Rheum 1989; 32: S 124.
Tipping PG, Hancock WW: Production of tumour necrosis factor and interleukin-1 by macrophages from human atheromatous plaques. Am J Pathol 1993; 142: 1721-1728.
Chouaib S, Bertoglio J, Blay JY, Marchiol-Fournigault C, Fradelizi D: Generation of lymphokine-?ctivated killer cells: synergy between tumour necrosis factor and interleukin 2. Proc Natl Acad Sci USA 1988; 85: 6875-6879.
Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr, Shepard HM: Recombinant human tumour necrosis factor-a: effects on proliferation of normal and transformed cells in vitro. Science 1985; 230: 944-945.
Wong GHW, Goeddel DV: Tumour necrosis factors-a and b inhibit virus replication and synergies with interferon’s. Nature 1986; 323: 819-822.
Taverne J, Matthews N, Depledge P, Playfair JHL: Malarial parasites and tumour cells are killed by the some component of tumour necrosis serum. Clin Exp Immunol 1984; 57: 293-300.
Havell EA: Evidence that tumour necrosis factor has an important role in antibacterial resistance. J Immunol 1989; 143: 2894-2899.
Dnarello, CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, et al: Tumour necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986; 163: 1433-1450.
Bertolini DR, Nedwin GE, Brimgman TS, Smith DD, Mundy GR: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986; 319: 516-518.
Hotamisligil. G, Murray D, Spiegelman BM: Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: central role of tumour necrosis factor-a. J Clin Invest 1994; 94: 1543-1549.
Tracey KJ, Beutler R, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al: Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-474.
Hotamísligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumour necrosis factor-a in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415.
Eigler A, Sinha B, Hartmann G, Endres S: Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 1997; 18: 487-492.
Tabib A, Leroux C, Mornex JF, Loire R: Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency virus-positive patients. Coron Artery Dis 2000; 11: 41-46.
Charles P, Elliot MJ, Davis D, Potter A, Antoni C, Breedueld FC, et al: Regulation of cytokines, cytokine inhibitor, and acute-phase proteins followin ant-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163: 1521-1528.
Morin CL, Schlaepfer IR, Eckel RH: Tumour necrosis factor-a eliminates binding of NF-Y and an octamer-bindin protein to the lipoprotein lipase promoter in 3T3-L 1 adipocites. J Clin Invest 1995; 95: 1684-1689.
Permutter DH, Dinarello CA, Punsel PI, Colten HR: Cachectin/tumour necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest 1986; 78: 1348 1354.
Tartaglia LA, Goeddel DV: Two TNF receptors. Immunol Today 1992; 13: 151-153.
Hobmam HP, Remy R, Pöschl B, VanLoon APGM: Tumour necrosis factor alpha and beta bind to the same two types of tumour necrosis factor receptors and maximally activate the transcription factor NF-kB at low receptor accuracy and within minutes after receptor binding. J Biol Chem 1990; 265: 15183-15188.
Tártaglia LA, Pennica D, Goeddel DV: Ligand passing: The 75 kDa tumour necrosis factor (TNF) receptor recruits TNF for signalling by the 55 kDa TNF receptor. J Biol Chem 1993; 268: 18542-18548.
Slowik MR, De Luca LG, Fiers W, Pober JS: Tumour necrosis factor activates human endothelial cells through the p55 tumour necrosis factor receptor but the p75 receptor contributes to activation at low tumour necrosis factor concentration. Am J Pathol 1993; 143: 1724-1730.
Shütze S, Berkovic D, Tomsing O, Unger C, Krönke M: Tumour necrosis factor induces rapid production of 1’2’diacylglycerol by a phosphatidylcholine-specific phospholipase C. J Exp Med 1991; 174: 975-988.
Meíchle A, Shütze S, Hensel G, Brunsing D, Krónke M: Protein kinase-C-independent activation of nuclear factor kB by tumour necrosis factor. J Biol Chem 1990; 265: 8339-8343.
47A. López-Marure R, Ventura JL, Sánchez L, Montaño F, Zentella A. Ceramide mimics tumour necrosis factor-a in the induction of cell cycle arrest in endothelial cells. Induction of the tumour suppressor p53 with decrease in retinoblastoma/protein levels. Eur J Biochem 2000; 267:4325-4333.
Wiegmann K, Shütze S, Machleidt T, Witte D, Krönke M: Functional Dichotomy of neutral acidic sphingomyelinases in tumour necrosis factor signalling. Cell 1994; 78: 1005-1015.
Liu, Mathias S, Koiesnick RN: Renaturation and tumour necrosis factor-a stimulation of a 97 kDa ceramide-?ctivated protein kinase. J Biol Chem 1994; 269: 3047 3052.
Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T: The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 1995; 2: 493-506.
Schütze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K, Krónke M: TNF activates NF-kB by phosphatidylcholine-specific phospholipase C-induced “acidic” sphingomyelin breakdown. Cell 1992; 71: 765-776.
Thanos D, Maniatis T: NF-kB: A lesson in family values. Cell 1995; 80: 529-532.
Dröge W, Schulze-Osthoff K, Mihm S, Galter D, Schenk H, Eck H-P: Functions of glutatione disulphide in immunology and immunopathology. FASEB J 1994; 8: 1131-1138.
Schreck R, Albemann K, Baeurele PA: Nuclear Factor kB: an oxidative stress responsive transcription factor of eukaryotic cells (a review), Free Radic Res Comun 1992; 17: 221-237.
Parhami F, Fang ZT, Fogelman AM, Andalibi A, Territo MC, Berliner JA: Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. J Clin Invest 1993; 92: 471-478.
Guja M, Bai W, Nadler JL, Natarajan R: Molecular mechanisms of tumour necrosis factor-alpha gene expression in monocytic cells via hyperglycaemia-induced oxidative stress-dependent and independent pathways. J Bíol Chem 2000; 275: 17728-17739.
Cavender D, Edelbaum D, Ziff M: Endothelial cell activation induced by tumour necrosis factor and, lymphotoxin. Am J Pathol 1989; 134: 551-560.
Becker BF, Heindl B, Kupatt C, Zahler S: Endothelial function and hemostasis. Z Kardiol 2000; 89: 160-167.
Stolpen AH, Guinan EC, Fiers W, Pober JS: Recombinant tumour necrosis factor and immune interferon act singly and in combination to reorganize human vascular endotelial cell monolayers. Am J Pathol 1986; 123: 16-24.
Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MJ Jr: Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes an related leukocyte cell lines. J Clin Invest 1985; 76: 2003-2011.
Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA: Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumour necrosis factor. Proc Natl Acad Sci USA 1985; 82: 8667-8671.
Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA Jr: Identification of inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987; 84: 9238-9242.
Szekanecz Z, Shah MR, Pearce WH, Koch AE: Intercellular adhesion molecule-1 (ICAM-1) expression and soluble ICAM-1 (sICAM-1) production by citokine-activated human aortic endothelial cells: a possible role for ICAM-I and sICAM-I in atherosclerotic aortic aneurysms. Clin Exp Immunol 1994; 98: 337-343.
Carlos TM, Schwartz BR, Kovach NL, Yee E, Rosso M, Osborn L et al: Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood 1990; 76: 965-970.
Ming WJ, Bersani L, Mantovani A: Tumour necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J Immunol. 1987; 138: 1469-1474.
Van der Wall AC, Das PK, Bentz van de Berg DB, van der Loos CM, Beeker AE: Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest 1989; 61: 166-170.
Endo K, Akahoshi T, Kashíwazaqui S: Additive effects of IL-1 and TNF on induction prostacyclin synthesis in human vascular endothelial cells. Biochem Biophys Res Com 1998; 156: 1007-1014.
Flect JC, Clinton SK, Salomon RN, Loppnow H, Libby P: Atherogenic diets enhanced endotoxin- stimulated interleukin-l and tumour necrosis factor gene expression in rabbit aortal. J Nutr 1992; 122: 294-305.
Barath P, Fishbcin MC, Cao J, Berenson J, Helfant RK Forrester JS: Detection and localization of tumour necrosis factor in human atheroma. Am J Cardiol 1990; 65: 297-302.
Rus HG, Niculescu F, Maicu R: Tumour necrosis factor-alpha in human arterial wall wit atherosclerosis. Atherosclerosis 1991; 89: 247-254.
Nagura H, Ohtani H: Expression of major histocompatibility class-II antigens by vascular endothelial cells leads to amplified immunoinflammatory processes. Acta Histochem Cytochem 1992; 25: 653-660.
Johnson DR, Pober JS: Tumour necrosis factor and immune interferon synergistically increase transcription of HLA class I heavy-and light-chain genes in vascular endothelium. Proc Natl Acad Sci USA 1990; 87: 5183-5187.
Van der Wal AC, Das PK, Tigges AJ, Becker AE: Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions. Am J Pathol 1992; 141: 1427-1433.
O’Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D et al: Vascular cell adhesion molecule-I is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest 1993; 92: 945-951.
Lei X, Buja LM. Measurement by quantitative reverse transcription-polymerase chain reaction of the levels of tumour necrosis factor alpha mRNA in atherosclerotic arteries in Watanabe Hereditable Hyperlipidemic Rabbits. Lab Invest 1996; 74: 136-145.
DeGraba TJ. Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque. Neurology 1997; 49: S15-S19.
Conway EM, Rosenberg RD. Tumour necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8: 5588-5592.
Nawroth PP, Stern DM. Modulation of endothelial cell haemostatic properties by tumour necrosis factor. J Exp Med 1986; 163: 740-745.
Fyfé A, Daly P, Galligan L, Piric L, Feindel C, Cardellia C. Coronary sinus sampling of cytokines after heart transplantation: evidence of macrophage activation and interleukin-4 production within the graft. J Am Coll Cardiol 1993; 21: 171-176.
Maury CPJ, Teppo AM. Circulating tumour necrosis factor-a (cachectin) in myocardial infarction. J Int Med 1989; 225: 333-336.
Barath P, Cao J, Forrester JS. Low density lipoprotein activates monocytes to express tumour necrosis factor. FEBS Letters 1990; 277: 180-184.
Toborek M, Hennig B. Is endothelial cell autocrine production of tumour necrosis factor a mediator of lipid induced endothelial dysfunction? Medical Hipotheses 1996; 47: 337-382.
Schreyer SA, Peschon JJ, LeBoeuf RC. Accelerated atherosclerosis in mice lacking tumour necrosis factor receptor p55. J Biol Chem 1996; 271: 26174-26178.
Paleolog EM, Delasalle S-AJ, Burman WA, Feldmann M. Functional activities of receptors of tumour necrosis factor alpha on human vascular endothelial cells. Blood 1994; 84: 2578-2590.
Mackay F, Loetscher H, Stueber D, Gehr G, Lesslauer W. Tumour necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type TNF-R55. J Exp Med 1993; 177: 1277-1286.
Peng Q, Wei Z, Lau BH. Pyconogenol inhibits tumour necrosis factor-alpha-induced nuclear factor Kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci 2000; 57: 834-841.
Müller G, Ayoub M, Storrz P, Rennecke J, Fabbro D, Pfizenmaier K. PKCz is a molecular switch in signal transduction of TNF-a, bifunctionally regulated by ceramide and arachidonic acid. EMBO J 1995; 14: 1961-1969.
Rodríguez E, Hernández A, López R, Paezk Massó F, Montaño LF. Chemokine secretion, but not its transcription, is inhibited by 17b-estradiol in TNF-alpha stimulated HUVEC’s. Cardiovascular Res (en revisión).
Read MA, Whitley MZ, Williams AJ, Collins T: NF-kB and IkBa: an inducible regulatory system in endothelial cell activation. J Exp Med 1994; 179: 503-512.
Ohta MY, Nagai Y, Takamura T, Nahora E, Kobayashi K. Inhibitory effect of trogliglitazone on TNF-alpha-induced expression of moncyte chemoattactant protein-1 (MCP-1) in human endothelial cells. Diabetes Res Clin Pract 2000; 48: 171-176.